Clinical Trial Update: Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial of selinexor (KPT-330) in metastatic triple-negative breast cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-30